Retro-inverso CendR peptide-mediated polyethyleneimine for intracranial glioblastoma-targeting gene therapy

Bioconjugate Chemistry

Volumn 25, Issue 2, 2014, Pages 414-423

  Wang, Jing ^a   Lei, Yang ^a   Xie, Cao ^a   Lu, Weiyue ^a   Wagner, Ernst ^a   Xie, Zuoxu ^a   Gao, Jie ^a   Zhang, Xiaoyu ^a   Yan, Zhiqiang ^b   Liu, Min ^a  

^a FUDAN UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EFFICIENCY; FLUORESCENCE IMAGING; GENE TRANSFER; MAMMALS; PEPTIDES; TUMORS;

GENE DELIVERY VECTORS; GENE VECTORS; GLIOBLASTOMAS; GLIOMA CELLS; NEUROPILINS; NON-VIRAL GENE DELIVERY; POLY(ETHYLENEIMINE); TARGETING LIGANDS; TRANSFECTION EFFICIENCY; TUMOR SPHEROID;

GENE THERAPY;

FLUORESCEIN ISOTHIOCYANATE; MACROGOL; NEUROPILIN 1; PEPTIDE; PLASMID DNA; POLYETHYLENEIMINE; RETRO INVERSO C END RULE PEPTIDE D; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GENE THERAPY; CELL STRAIN HEK293; CELL SURVIVAL; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOTOXICITY; GENE EXPRESSION; GENE VECTOR; GLIOBLASTOMA; GLIOMA CELL; HUMAN; HUMAN CELL; IN VITRO GENE TRANSFER; IN VIVO GENE TRANSFER; MALE; MOUSE; MTT ASSAY; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PARTICLE SIZE; PROTEIN DEGRADATION; PROTEIN STABILITY; RAT; SURVIVAL TIME; SYNTHESIS; TUMOR SPHEROID; ZETA POTENTIAL;

BRAIN NEOPLASMS; GENETIC THERAPY; GLIOBLASTOMA; HUMANS; PEPTIDES; POLYETHYLENEIMINE;

EID: 84894428768     PISSN: 10431802     EISSN: 15204812     Source Type: Journal    
DOI: 10.1021/bc400552t     Document Type: Article

References (43)

1. Tambet, T., Sugahara, K. N., and Ruoslahti, E. (2009) C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration Proc. Natl. Acad. Sci. U.S.A. 106, 16157-16162
2. Haubner, R., Finsinger, D., and Kessler, H. (1997) Stereoisomeric peptide libraries and peptidomimetics for designing selective inhibitors of the alpha(V)beta(3) integrin for a new cancer therapy Angew. Chem., Int. Ed. 36, 1375-1389
3. Hoffman, J. A., Giraudo, E., Singh, M., Zhang, L. L., Inoue, M., Porkka, K., Hanahan, D., and Ruoslahti, E. (2003) Progressive vascular changes in a transgenic mouse model of squamous cell carcinoma Cancer Cell 4, 383-391
4. Gregorc, V., Citterio, G., Vitali, G., Spreafico, A., Scifo, P., Borri, A., Donadoni, G., Rossoni, G., Corti, A., Caligaris-Cappio, F., Del Maschio, A., Esposito, A., De Cobelli, F., Dell'Acqua, F., Troysi, A., Bruzzi, P., Lambiase, A., and Bordignon, C. (2010) Defining the optimal biological dose of NGR-hTNF, a selective vascular targeting agent, in advanced solid tumours Eur. J. Cancer 46, 198-206
5. Sugahara, K. N., Teesalu, T., Karmali, P. P., Kotamraju, V. R., Agemy, L., Greenwald, D. R., and Ruoslahti, E. (2010) Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs Science 328, 1031-1035
6. Pasqualini, R., Koivunen, E., Kain, R., Lahdenranta, J., Sakamoto, M., Stryhn, A., Ashmun, R. A., Shapiro, L. H., Arap, W., and Ruoslahti, E. (2000) Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis Cancer Res. 60, 722-727
7. Pasqualini, R., Koivunen, E., and Ruoslahti, E. (1997) alpha v Integrins as receptors for tumor targeting by circulating ligands Nat. Biotechnol. 15, 542-546
8. Gregorc, V., Santoro, A., Bennicelli, E., Punt, C., Citterio, G., Timmer-Bonte, J., Cappio, F. C., Lambiase, A., Bordignon, C., and van Herpen, C. (2009) Phase Ib study of NGR-hTNF, a selective vascular targeting agent, administered at low doses in combination with doxorubicin to patients with advanced solid tumours Br. J. Cancer 101, 219-224
9. Schorderet, D. F., Manzi, V. D., Canola, K., Bonny, C., Arsenijevic, Y., Munier, F. L., and Maurer, F. (2005) D-TAT transporter as an ocular peptide delivery system Clin. Exp. Ophthalmol. 33, 628-635
10. Sadowski, M., Pankiewicz, J., Scholtzova, H., Li, Y. S., Quartermain, D., Duff, K., and Wisniewski, T. (2004) Links between the pathology of Alzheimer's disease and vascular dementia Neurochem. Res. 29, 1257-1266
11. Goodman, M. and Chorev, M. (1979) Concept of linear modified retro-peptide structures Acc. Chem. Res. 12, 1-7
12. Guichard, G., Benkirane, N., Zeder-Lutz, G., Vanregenmortel, M., Briand, J. P., and Muller, S. (1994) Antigenic mimicry of natural l -peptides with retro-inverso-peptidomimetics Proc. Natl. Acad. Sci. U.S.A. 91, 9765-9769
13. Briand, J. P., Guichard, G., Dumortier, H., and Muller, S. (1995) Retro-inverso peptidomimetics as new immunological probes-validation and application to the detection of antibodies in pheumatic diseases J. Biol. Chem. 270, 20686-20691
14. Taylor, E. M., Otero, D. A., Banks, W. A., and O'Brien, J. S. (2000) Retro-inverso prosaptide peptides retain bioactivity, are stable in vivo, and are blood-brain barrier permeable J. Pharmacol. Exp. Ther. 295, 190-194
15. Li, Y., Lei, Y., Wagner, E., Xie, C., Lu, W. Y., Zhu, J. H., Shen, J., Wang, J., and Liu, M. (2013) Potent retro-inverso d -peptide for simultaneous targeting of angiogenic blood vasculature and tumor cells Bioconjugate Chem. 24, 133-143
16. Kolodkin, A. L., Levengood, D. V., Rowe, E. G., Tai, Y. T., Giger, R. J., and Ginty, D. D. (1997) Neuropilin is a Semaphorin III receptor Cell 90, 753-762
17. Soker, S., Takashima, S., Miao, H. Q., Neufeld, G., and Klagsbrun, M. (1998) Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor Cell 92, 735-745
18. Oh, H., Takagi, H., Otani, A., Koyama, S., Kemmochi, S., Uemura, A., and Honda, Y. (2002) Selective induction of neuropilin-1 by vascular endothelial growth factor (VEGF): A mechanism contributing to VEGF-induced angiogenesis Proc. Natl. Acad. Sci. U.S.A. 99, 383-388
19. Osada, H., Tokunaga, T., Nishi, M., Hatanaka, H., Abe, Y., Tsugu, A., Kijima, H., Yamazaki, H., Ueyama, Y., and Nakamura, M. (2004) Overexpression of the neuropilin 1 (NRP1) gene correlated with poor prognosis in human glioma Anticancer Res. 24, 547-552
20. Nasarre, C., Roth, M., Jacob, L., Roth, L., Koncina, E., Thien, A., Labourdette, G., Poulet, P., Hubert, P., Cremel, G., Roussel, G., Aunis, D., and Bagnard, D. (2010) Peptide-based interference of the transmembrane domain of neuropilin-1 inhibits glioma growth in vivo Oncogene 29, 2381-2392
21. Du, J., Lu, W. L., Ying, X., Liu, Y., Du, P., Tian, W., Men, Y., Guo, J., Zhang, Y., Li, R. J., Zhou, J., Lou, J. N., Wang, J. C., Zhang, X., and Zhang, Q. (2009) Dual-targeting topotecan liposomes modified with tamoxifen and wheat germ agglutinin significantly improve drug transport across the blood-brain barrier and survival of brain tumor-bearing animals Mol. Pharmaceutics 6, 905-917
22. Gao, H., Qian, J., Yang, Z., Pang, Z., Zhang, S., and Zhang, Q. (2012) Whole-cell SELE X aptamer-functionalised poly(ethyleneglycol)-poly(ε- caprolactone) nanoparticles for enhance d targeted glioblastoma therapy Biomaterials 33, 6264-6272
23. Zhan, C. Y., Gu, B., Xie, C., Li, J., Liu, Y., and Lu, W. Y. (2010) Cyclic RGD conjugated poly(ethylene glycol)-co-poly(lactic acid) micelle enhances paclitaxel anti-glioblastoma effect J. Controlled Release 143, 136-142
24. Luo, X., Pan, S. R., Feng, M., Wen, Y. T., and Zhang, W. (2010) Stability of poly(ethylene glycol)-graft-polyethylenimine copolymer/DNA complexes: influences of PEG molecular weight and PEGylation degree J. Mater. Sci.-Mater. Med. 21, 597-607
25. Petersen, H., Fechner, P. M., Martin, A. L., Kunath, K., Stolnik, S., Roberts, C. J., Fischer, D., Davies, M. C., and Kissel, T. (2002) Polyethylenimine-graft-poly(ethylene glycol) copolymers: Influence of copolymer block structure on DNA complexation and biological activities as gene delivery system Bioconjugate Chem. 13, 845-854
26. Neu, M., Germershaus, O., Behe, M., and Kissel, T. (2007) Bioreversibly crosslinked polyplexes of PEI and high molecular weight PEG show extended circulation times in vivo J. Controlled Release 124, 69-80
27. Jain, R. K., Di Tomaso, E., Duda, D. G., Loeffler, J. S., Sorensen, A. G., and Batchelor, T. T. (2007) Angiogenesis in brain tumours Nat. Rev. Neurosci. 8, 610-622
28. Lima, F., Kahn, S. A., Soletti, R. C., Biasoli, D., Alves, T., Da Fonseca, A., Garcia, C., Romao, L., Brito, J., Holanda-Afonso, R., Faria, J., Borges, H., and Moura-Neto, V. (2012) Glioblastoma: Therapeutic challenges, what lies ahead BBA-Rev. Cancer 1826, 338-349
29. Meng, Q. G., Yu, M., Gu, B., Li, J., Liu, Y., Zhan, C. Y., Xie, C., Zhou, J. P., and Lu, W. Y. (2010) Myristic acid-conjugated polyethylenimine for brain-targeting delivery: in vivo and ex vivo imaging evaluation J. Drug Target. 18, 438-446
30. Li, J. F., Zhou, L., Ye, D. Y., Huang, S. X., Shao, K., Huang, R. Q., Han, L., Liu, Y., Liu, S. H., Ye, L. Y., Lou, J. N., and Jiang, C. (2011) Choline-derivate-modified nanoparticles for brain-targeting gene delivery Adv. Mater. 23, 4516-4521
31. Gerstner, E. R. and Batchelor, T. T. (2012) Antiangiogenic therapy for glioblastoma Cancer J. 18, 45-50
32. Huang, S. X., Li, J. F., Han, L., Liu, S. H., Ma, H. J., Huang, R. Q., and Jiang, C. (2011) Dual targeting effect of Angiopep-2-modified, DNA-loaded nanoparticles for glioma Biomaterials 32, 6832-6838
33. Schiffelers, R. M., Ansari, A., Xu, J., Zhou, Q., Tang, Q., Storm, G., Molema, G., Lu, P. Y., Scaria, P. V., and Woodle, M. C. (2004) Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle Nucleic Acids Res. 32, e149
34. Gao, H. L., Qian, J., Cao, S. J., Yang, Z., Pang, Z. Q., Pan, S. Q., Fan, L., Xi, Z. J., Jiang, X. G., and Zhang, Q. Z. (2012) Precise glioma targeting of and penetration by aptamer and peptide dual-functioned nanoparticles Biomaterials 33, 5115-5123
35. Heldin, C., Rubin, K., Pietras, K., and Östman, A. (2004) High interstitia fluid pressure-an obstacle in cancer therapy Nat. Rev. Cancer 4, 806-813
36. Xin, H. L., Jiang, X. Y., Gu, J. J., Sha, X. Y., Chen, L. C., Law, K., Chen, Y. Z., Wang, X., Jiang, Y., and Fang, X. L. (2011) Angiopep-conjugated poly(ethylene glycol)-co-poly(epsilon-caprolactone) nanoparticles as dual-targeting drug delivery system for brain glioma Biomaterials 32, 4293-4305
37. Zhan, C. Y., Li, B., Hu, L. J., Wei, X. L., Feng, L. Y., Fu, W., and Lu, W. Y. (2011) Micelle-based brain-targeted drug delivery enabled by a nicotine acetylcholine receptor ligand Angew. Chem., Int. Ed. 50, 5482-5485
38. Hu, Q. Y., Gu, G. Z., Liu, Z. Y., Jiang, M. Y., Kang, T., Miao, D. Y., Tu, Y. F., Pang, Z. Q., Song, Q. X., Yao, L., Xia, H. M., Chen, H. Z., Jiang, X. G., Gao, X. L., and Chen, J. (2013) F3 peptide-functionalized PEG-PLA nanoparticles co-administrated with tLyp-1 peptide for anti-glioma drug delivery Biomaterials 34, 1135-1145
39. Tugyi, R., Uray, K., Ivan, D., Fellinger, E., Perkins, A., and Hudecz, F. (2005) Partial d -amino acid substitution: Improved enzymatic stability and preserved Ab recognition of a MUC2 epitope peptide Proc. Natl. Acad. Sci. U.S.A. 102, 413-418
40. Powell, M. F., Stewart, T., Otvos, L., Urge, L., Gaeta, F., Sette, A., Arrhenius, T., Thomson, D., Soda, K., and Colon, S. M. (1993) Peptide stability in drug development 0.2. effect of single Amino-Acid substitution and glycosylation on peptide reactivity in human serum Pharm. Res. 10, 1268-1273
41. Galati, R., Verdina, A., Falasca, G., and Chersi, A. (2003) Increased resistance of peptides to serum proteases by modification of their amino groups Z. Naturforsch. C 58, 558-561
42. Cardo-Vila, M., Giordano, R. J., Sidman, R. L., Bronk, L. F., Fan, Z., Mendelsohn, J., Arap, W., and Pasqualini, R. (2010) From combinatorial peptide selection to drug prototype(II): Targeting the epidermal growth factor receptor pathway Proc. Natl. Acad. Sci. U.S.A. 107, 5118-5123
43. Sakurai, K., Chung, H. S., and Kahne, D. (2004) Use of a retroinverso p53 peptide as an inhibitor of MDM2 J. Am. Chem. Soc. 126, 16288-16289